Compare Logitech International SA (LOGI) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Mesoblast Limited — how do they compare? Logitech International SA trades at $103.82 (market cap $14.96B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: Logitech International SA is far larger — about 6.8× Mesoblast Limited's market cap, and Logitech International SA pays a 1.64% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| LOGI | MESO | |
|---|---|---|
Market Cap | $14.96B | $2.21B |
Sector | Technology | Technology |
52-Week High | $126.69 | $20.96 |
52-Week Low | $85.84 | $12.88 |
Enterprise Value | $13.30B | $2.21B |
Dividend Yield | 1.64% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
